stockportfolio.pro
Corcept Therapeutics Incorporated P/E Ratio 2000–2025
Corcept Therapeutics Incorporated (CORT) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -3.5%/yr over 25 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 42.44 | +3.6% |
| FY 2024 | 40.97 | +18.6% |
| FY 2023 | 34.55 | +48.0% |
| FY 2022 | 23.34 | +4.9% |
| FY 2021 | 22.25 | -27.7% |
| FY 2020 | 30.78 | +95.9% |
| FY 2019 | 15.71 | -29.4% |
| FY 2018 | 22.27 | +28.2% |
| FY 2017 | 17.37 | -83.3% |
| FY 2016 | 103.71 | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
| FY 2008 | — | — |
| FY 2007 | — | — |
| FY 2006 | — | — |
| FY 2005 | — | — |
| FY 2004 | — | — |
| FY 2003 | — | — |
| FY 2002 | — | — |
| FY 2001 | — | — |
| FY 2000 | — | — |
Source: Corcept Therapeutics Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Corcept Therapeutics Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCorcept Therapeutics Incorporated — frequently asked questions
What is Corcept Therapeutics Incorporated's price-to-earnings ratio?
Corcept Therapeutics Incorporated (CORT) reported price-to-earnings ratio of 42.44 for fiscal year 2025, per its SEC filings.
How has Corcept Therapeutics Incorporated's price-to-earnings ratio changed over time?
Between fiscal 2000 and 2025, CORT's price-to-earnings ratio declined at roughly 3.5% per year (compound annual rate), from 103.71 to 42.44.
Where does this data come from?
Figures are computed from Corcept Therapeutics Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.